UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 305

Sortiert nach

An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas

Annals of oncology, 2013-01, Vol.24 (1), p.257-263

2013

Volltextzugriff (PDF)

Clinical outcomes and safety with trabectedin therapy in patients with advanced soft tissue sarcomas following failure of prior chemotherapy: results of a worldwide expanded access program study

Annals of oncology, 2013-06, Vol.24 (6), p.1703-1709

2013

Volltextzugriff (PDF)

Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy

Annals of oncology, 2016-09, Vol.27 (9), p.1794-1799

2016

Volltextzugriff (PDF)

Circulating tumor DNA analysis of the phase III VOYAGER trial: KIT mutational landscape and outcomes in patients with advanced gastrointestinal stromal tumor treated with avapritinib or regorafenib

Annals of oncology, 2023-07, Vol.34 (7), p.615-625

2023

Volltextzugriff (PDF)

Trabectedin is a feasible treatment for soft tissue sarcoma patients regardless of patient age: a retrospective pooled analysis of five phase II trials

British journal of cancer, 2013-10, Vol.109 (7), p.1717-1724

2013

Volltextzugriff (PDF)

Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals

Annals of oncology, 2019-10, Vol.30 (10), p.1647-1652

2019

Volltextzugriff (PDF)

Efficacy and tolerability of trabectedin in elderly patients with sarcoma: subgroup analysis from a phase III, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma

Annals of oncology, 2018-09, Vol.29 (9), p.1995-2002

2018

Volltextzugriff (PDF)

Evaluation of nilotinib in advanced GIST previously treated with imatinib and sunitinib

Cancer chemotherapy and pharmacology, 2012-04, Vol.69 (4), p.977-982

2012

Volltextzugriff (PDF)

Initial results of phase I study of DCC-2618, a broad-spectrum KIT and PDGFRa inhibitor, in patients (pts) with gastrointestinal stromal tumor (GIST) by number of prior regimens

Annals of oncology, 2018-10, Vol.29, p.viii576-viii577

2018

Volltextzugriff (PDF)

Synovial sarcoma: characteristics, challenges and evolving therapeutic strategies

ESMO open, 2023-10, Vol.8 (5), p.101618-101618, Article 101618

2023

Volltextzugriff (PDF)

A nonrandom association of gastrointestinal stromal tumor (GIST) and desmoid tumor (deep fibromatosis): case series of 28 patients

Annals of oncology, 2012-05, Vol.23 (5), p.1335-1340

2012

Volltextzugriff (PDF)

Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro

British journal of cancer, 2008-11, Vol.99 (9), p.1415-1425

2008

Volltextzugriff (PDF)

Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy

Annals of oncology, 2013-02, Vol.24 (2), p.537-542

2013

Volltextzugriff (PDF)

A Phase I Study of Temsirolimus and Bryostatin‐1 in Patients With Metastatic Renal Cell Carcinoma and Soft Tissue Sarcoma

The oncologist (Dayton, Ohio), 2014-04, Vol.19 (4), p.354-355

2014

Volltextzugriff (PDF)

A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies

Annals of oncology, 2008-10, Vol.19 (10), p.1802-1809

2008

Volltextzugriff (PDF)

Correlation of ctDNA and response in patients (pts) with PDGFRα D842 GIST treated with avapritinib

Annals of oncology, 2018-10, Vol.29, p.viii584-viii584

2018

Volltextzugriff (PDF)

Preliminary safety and activity in a first-in-human phase 1 study of BLU-285, a potent, highly-selective inhibitor of KIT and PDGFRα activation loop mutants in advanced gastrointestinal stromal tumor (GIST)

European journal of cancer (1990), 2016-12, Vol.69, p.S4-S4

2016

Volltextzugriff (PDF)

A USA registry of gastrointestinal stromal tumor patients: changes in practice over time and differences between community and academic practices

Annals of oncology, 2011-11, Vol.22 (11), p.2523-2529

2011

Volltextzugriff (PDF)

1321 Efficacy and safety of trabectedin (T) or dacarbazine (D) in an elderly patient subgroup (65 years) with advanced leiomyosarcoma (LMS) or liposarcoma (LPS) after prior chemotherapy

European journal of cancer (1990), 2015-09, Vol.51, p.S194-S194

2015

Volltextzugriff (PDF)

Imatinib-Resistant GIST Metastases: Predicting Outcomes of Surgical Resection

The Journal of surgical research, 2012, Vol.172 (2), p.194-194

2012

Volltextzugriff (PDF)

Considerations in natural gas and LNG price review claim quantification

Journal of world energy law & business, 2015-04, Vol.8 (2), p.103-115

2015

Volltextzugriff (PDF)

Validating a gene expression signature proposed to differentiate liposarcomas that use different telomere maintenance mechanisms

Oncogene, 2012-01, Vol.31 (2), p.265-266

2012

Volltextzugriff (PDF)

1138 POSTER Neutropenia as a Biomarker of Sunitinib Efficacy in Patients (Pts) With Gastrointestinal Stromal Tumour (GIST)

European journal of cancer (1990), 2011, Vol.47, p.S135-S135

2011

Volltextzugriff (PDF)

Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor

Journal of clinical oncology, 2003-12, Vol.21 (23), p.4342-4349

2003

Volltextzugriff (PDF)

1 – 25 von 305

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(280)
Mit Volltextzugriff
(266)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(120)
Humans
(109)
Life Sciences & Biomedicine
(108)
Oncology
(79)
Female
(58)
Male
(57)
Adult
(45)
Middle Aged
(44)
Aged
(42)
Biological And Medical Sciences
(39)
Medical Sciences
(39)
Tumors
(37)
Imatinib Mesylate
(29)
Benzamides
(26)
Pharmacology. Drug Treatments
(22)
Treatment Outcome
(22)
Antineoplastic Agents
(20)
Gastrointestinal Stromal Tumors - Drug Therapy
(20)
Aged, 80 And Over
(19)
Surgery
(19)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network

An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas

Clinical outcomes and safety with trabectedin therapy in patients with advanced soft tissue sarcomas following failure of prior chemotherapy: results of a worldwide expanded access program study

Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy

Circulating tumor DNA analysis of the phase III VOYAGER trial: KIT mutational landscape and outcomes in patients with advanced gastrointestinal stromal tumor treated with avapritinib or regorafenib

Trabectedin is a feasible treatment for soft tissue sarcoma patients regardless of patient age: a retrospective pooled analysis of five phase II trials

Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals

Efficacy and tolerability of trabectedin in elderly patients with sarcoma: subgroup analysis from a phase III, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma

Evaluation of nilotinib in advanced GIST previously treated with imatinib and sunitinib

Initial results of phase I study of DCC-2618, a broad-spectrum KIT and PDGFRa inhibitor, in patients (pts) with gastrointestinal stromal tumor (GIST) by number of prior regimens

Synovial sarcoma: characteristics, challenges and evolving therapeutic strategies

A nonrandom association of gastrointestinal stromal tumor (GIST) and desmoid tumor (deep fibromatosis): case series of 28 patients

Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro

Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy

A Phase I Study of Temsirolimus and Bryostatin‐1 in Patients With Metastatic Renal Cell Carcinoma and Soft Tissue Sarcoma

A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies

Correlation of ctDNA and response in patients (pts) with PDGFRα D842 GIST treated with avapritinib

Preliminary safety and activity in a first-in-human phase 1 study of BLU-285, a potent, highly-selective inhibitor of KIT and PDGFRα activation loop mutants in advanced gastrointestinal stromal tumor (GIST)

A USA registry of gastrointestinal stromal tumor patients: changes in practice over time and differences between community and academic practices

1321 Efficacy and safety of trabectedin (T) or dacarbazine (D) in an elderly patient subgroup (65 years) with advanced leiomyosarcoma (LMS) or liposarcoma (LPS) after prior chemotherapy

Imatinib-Resistant GIST Metastases: Predicting Outcomes of Surgical Resection

Considerations in natural gas and LNG price review claim quantification

Validating a gene expression signature proposed to differentiate liposarcomas that use different telomere maintenance mechanisms

1138 POSTER Neutropenia as a Biomarker of Sunitinib Efficacy in Patients (Pts) With Gastrointestinal Stromal Tumour (GIST)

Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor

Suchergebnisse filtern